The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA

Journal of Pathology

Volumn 226, Issue 2, 2012, Pages 326-337

  Crossan, Gerry P ^a   Patel, Ketan J ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Btbd12; crosslink; DNA repair; Fanconi anaemia; genome instability; Slx4

Indexed keywords

CISPLATIN; DNA; ENDONUCLEASE; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; FANCONI ASSOCIATED NUCLEASE 1; GENE PRODUCT; MITOMYCIN C; MUTAGENIC AGENT; TRANSCRIPTION FACTOR RUNX1; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; BONE MARROW DEPRESSION; CANCER SUSCEPTIBILITY; CELL DAMAGE; CELL DEATH; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CONGENITAL MALFORMATION; CYTOGENETICS; DEVELOPMENTAL DISORDER; DISEASE COURSE; DNA CROSS LINKING; DNA DAMAGE; DNA METABOLISM; DNA REPAIR; DOUBLE STRANDED DNA BREAK; EARLY MENOPAUSE; EMBRYO DEVELOPMENT; FANCONI ANEMIA; FEMALE INFERTILITY; GENE INACTIVATION; GENE LOCATION; GENE REPLICATION; GENOMIC INSTABILITY; GERM CELL; HOMOLOGOUS RECOMBINATION; HUMAN; LETHALITY; LEUKEMIA CELL; MALE FERTILITY; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NONHUMAN; ONCOGENE; ONSET AGE; OVARY INSUFFICIENCY; PANCYTOPENIA; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SISTER CHROMATID EXCHANGE; SOMATIC HYPERMUTATION; SPERMATOZOON COUNT; SPONTANEOUS ABORTION; STEM CELL DEFECT; XENOPUS;

DNA DAMAGE; DNA REPAIR; DNA REPLICATION; ENDONUCLEASES; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASMS;

EID: 82755184119     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.3002     Document Type: Review

References (151)

1. Lobitz S, Velleuer E,. Guido Fanconi (1892-1979): a jack of all trades. Nat Rev Cancer 2006; 6: 893-898. (Pubitemid 44629901)
2. Joenje H, Patel KJ,. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2001; 2: 446-457. (Pubitemid 33673411)
3. Auerbach AD,. Fanconi anemia and its diagnosis. Mutat Res 2009; 668: 4-10.
4. Cox PM, Gibson RA, Morgan N, et al., VACTERL with hydrocephalus in twins due to Fanconi anemia (FA): mutation in the FAC gene. Am J Med Genet 1997; 68: 86-90. (Pubitemid 27023848)
5. Holden ST, Cox JJ, Kesterton I, et al., Fanconi anaemia complementation group B presenting as X-linked VACTERL with hydrocephalus syndrome. J Med Genet 2006; 43: 750-754. (Pubitemid 44483919)
6. Bremer M, Schindler D, Gross M, et al., Fanconi's anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy. Strahlenther Onkol 2003; 179: 748-753. (Pubitemid 37376989)
7. Kutler DI, Singh B, Satagopan J, et al., A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249-1256. (Pubitemid 36182492)
8. Porteous ME, Cross I, Burn J,. VACTERL with hydrocephalus: one end of the Fanconi anemia spectrum of anomalies? Am J Med Genet 1992; 43: 1032-1034.
9. Alter BP,. Hydrocephalus in Fanconi anemia. Am J Med Genet 1993; 45: 785.
10. Liu TX, Howlett NG, Deng M, et al., Knockdown of zebrafish Fancd2 causes developmental abnormalities via p53-dependent apoptosis. Dev Cell 2003; 5: 903-914. (Pubitemid 37527690)
11. Butturini A, Gale RP, Verlander PC, et al., Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994; 84: 1650-1655. (Pubitemid 24273037)
12. Rosenberg PS, Huang Y, Alter BP,. Individualized risks of first adverse events in patients with Fanconi anemia. Blood 2004; 104: 350-355. (Pubitemid 38900014)
13. Tulpule A, Lensch MW, Miller JD, et al., Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood 2010; 115: 3453-3462.
14. Nabhan SK, Bitencourt MA, Duval M, et al., Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica 2010; 95: 1783-1787.
15. Giampietro PF, Verlander PC, Davis JG, et al., Diagnosis of Fanconi anemia in patients without congenital malformations: an international Fanconi Anemia Registry Study. Am J Med Genet 1997; 68: 58-61. (Pubitemid 27023842)
16. Alter BP, Frissora CL, Halperin DS, et al., Fanconi's anaemia and pregnancy. Br J Haematol 1991; 77: 410-418.
17. Parmar K, D'Andrea A, Niedernhofer LJ,. Mouse models of Fanconi anemia. Mutat Res 2009; 668: 133-140.
18. Crossan GP, van der Weyden L, Rosado IV, et al., Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet 2011; 43: 147-152.
19. Houghtaling S, Timmers C, Noll M, et al., Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 2003; 17: 2021-2035. (Pubitemid 36999328)
20. Agoulnik AI, Lu B, Zhu Q, et al., A novel gene, Pog, is necessary for primordial germ cell proliferation in the mouse and underlies the germ cell deficient mutation, gcd. Hum Mol Genet 2002; 11: 3047-3053. (Pubitemid 35414818)
21. Cheng NC, van de Vrugt HJ, van der Valk MA, et al., Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet 2000; 9: 1805-1811. (Pubitemid 30608614)
22. Chen M, Tomkins DJ, Auerbach W, et al., Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia. Nat Genet 1996; 12: 448-451. (Pubitemid 26105940)
23. Whitney MA, Royle G, Low MJ, et al., Germ cell defects and hematopoietic hypersensitivity to γ-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood 1996; 88: 49-58. (Pubitemid 26230670)
24. Koomen M, Cheng NC, van de Vrugt HJ, et al., Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice. Hum Mol Genet 2002; 11: 273-281. (Pubitemid 34173356)
25. Kim JM, Parmar K, Huang M, et al., Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell 2009; 16: 314-320.
26. Bakker ST, van de Vrugt HJ, Rooimans MA, et al., Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. Hum Mol Genet 2009; 18: 3484-3495.
27. Holloway JK, Mohan S, Balmus G, et al., Mammalian BTBD12 (SLX4) protects against genomic instability during mammalian spermatogenesis. PLoS Genet 2011; 7: e1002094.
28. Nadler JJ, Braun RE,. Fanconi anemia complementation group C is required for proliferation of murine primordial germ cells. Genesis 2000; 27: 117-123.
29. Alter BP, Caruso JP, Drachtman RA, et al., Fanconi anemia: myelodysplasia as a predictor of outcome. Cancer Genet Cytogenet 2000; 117: 125-131. (Pubitemid 30125811)
30. Rackoff WR, Orazi A, Robinson CA, et al., Prolonged administration of granulocyte colony-stimulating factor (filgrastim) to patients with Fanconi anemia: a pilot study. Blood 1996; 88: 1588-1593. (Pubitemid 26307053)
31. Alter BP, Joenje H, Oostra AB, et al., Fanconi anemia: adult head and neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg 2005; 131: 635-639. (Pubitemid 41058056)
32. Alter BP, Greene MH, Velazquez I, et al., Cancer in Fanconi anemia. Blood 2003; 101: 2072.
33. Rosenberg PS, Greene MH, Alter BP,. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822-826. (Pubitemid 36139345)
34. Hofmann WK, Koeffler HP,. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16. (Pubitemid 40299770)
35. Hasle H, Baumann I, Bergstrasser E, et al., The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004; 18: 2008-2014. (Pubitemid 40028428)
36. Quentin S, Cuccuini W, Ceccaldi R, et al., Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 2011; 117: e161-170.
37. van Zeeburg HJ, Snijders PJ, Wu T, et al., Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst 2008; 100: 1649-1653.
38. Rosenberg PS, Alter BP, Ebell W,. Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry. Haematologica 2008; 93: 511-517. (Pubitemid 351536378)
39. Maia AT, van der Velden VH, Harrison CJ, et al., Prenatal origin of hyperdiploid acute lymphoblastic leukemia in identical twins. Leukemia 2003; 17: 2202-2206. (Pubitemid 37428387)
40. Jones LK, Neat MJ, van Delft FW, et al., Cryptic rearrangement involving MLL and AF10 occurring in utero. Leukemia 2003; 17: 1667-1669. (Pubitemid 36986972)
41. Broadfield ZJ, Hain RD, Harrison CJ, et al., Complex chromosomal abnormalities in utero, 5 years before leukaemia. Br J Haematol 2004; 126: 307-312. (Pubitemid 39005710)
42. Greaves M,. In utero origins of childhood leukaemia. Early Hum Dev 2005; 81: 123-129. (Pubitemid 40221990)
43. Macmahon B, Levy MA,. Prenatal origin of childhood leukemia. Evidence from twins. N Engl J Med 1964; 270: 1082-1085.
44. Miller RW,. Deaths from childhood leukemia and solid tumors among twins and other sibs in the United States, 1960-67. J Natl Cancer Inst 1971; 46: 203-209.
45. Hemminki K, Jiang Y,. Risks among siblings and twins for childhood acute lymphoid leukaemia: results from the Swedish Family Cancer Database. Leukemia 2002; 16: 297-298. (Pubitemid 34145149)
46. Greaves MF, Maia AT, Wiemels JL, et al., Leukemia in twins: lessons in natural history. Blood 2003; 102: 2321-2333. (Pubitemid 37193565)
47. Clarkson BD, Boyse EA,. Possible explanation of the high concordance for acute leukaemia in monozygotic twins. Lancet 1971; 1: 699-701.
48. Greaves MF, Wiemels J,. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003; 3: 639-649. (Pubitemid 37328819)
49. van Dijk BA, Boomsma DI, de Man AJ,. Blood group chimerism in human multiple births is not rare. Am J Med Genet 1996; 61: 264-268.
50. Thompson LH, Hinz JM,. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 2009; 668: 54-72.
51. Patel KJ, Joenje H,. Fanconi anemia and DNA replication repair. DNA Repair (Amst) 2007; 6: 885-890. (Pubitemid 46880469)
52. Saris CP, van de Vaart PJ, Rietbroek RC, et al., In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 1996; 17: 2763-2769. (Pubitemid 27037637)
53. Harrington CF, Le Pla RC, Jones GD, et al., Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. Chem Res Toxicol 2010; 23: 1313-1321.
54. Auerbach AD, Wolman SR,. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976; 261: 494-496.
55. de Winter JP, Joenje H,. The genetic and molecular basis of Fanconi anemia. Mutat Res 2009; 668: 11-19.
56. Stoepker C, Hain K, Schuster B, et al., SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet 2011; 43: 138-141.
57. Kim Y, Lach FP, Desetty R, et al., Mutations of the SLX4 gene in Fanconi anemia. Nat Genet 2011; 43: 142-146.
58. Vaz F, Hanenberg H, Schuster B, et al., Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42: 406-409.
59. Strathdee CA, Gavish H, Shannon WR, et al., Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992; 358: 434.
60. Faivre L, Guardiola P, Lewis C, et al., Association of complementation group and mutation type with clinical outcome in fanconi anemia. European Fanconi Anemia Research Group. Blood 2000; 96: 4064-4070.
61. Cleton-Jansen AM, Moerland EW, Pronk JC, et al., Mutation analysis of the Fanconi anaemia A gene in breast tumours with loss of heterozygosity at 16q24.3. Br J Cancer 1999; 79: 1049-1052. (Pubitemid 29087874)
62. Demuth I, Wlodarski M, Tipping AJ, et al., Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9. Eur J Hum Genet 2000; 8: 861-868.
63. D'Souza F, Usha MK, Subba Rao SD,. Fanconi's anemia in monozygotic twins. Indian J Pediatr 2007; 74: 859-861. (Pubitemid 350243651)
64. Koc A, Pronk JC, Alikasifoglu M, et al., Variable pathogenicity of exon 43del (FAA) in four Fanconi anaemia patients within a consanguineous family. Br J Haematol 1999; 104: 127-130. (Pubitemid 29037030)
65. Mankad A, Taniguchi T, Cox B, et al., Natural gene therapy in monozygotic twins with Fanconi anemia. Blood 2006; 107: 3084-3090.
66. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al., Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet 1997; 5: 137-148. (Pubitemid 27356701)
67. Soulier J, Leblanc T, Larghero J, et al., Detection of somatic mosaicism and classification of Fanconi anemia patients by analysis of the FA/BRCA pathway. Blood 2005; 105: 1329-1336. (Pubitemid 40170910)
68. Zhang XY, Langenick J, Traynor D, et al., Xpf and not the Fanconi anaemia proteins or Rev3 accounts for the extreme resistance to cisplatin in Dictyostelium discoideum. PLoS Genet 2009; 5: e1000645.
69. Garcia-Higuera I, Taniguchi T, Ganesan S, et al., Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001; 7: 249-262. (Pubitemid 32206493)
70. Wang X, Andreassen PR, D'Andrea AD,. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin. Mol Cell Biol 2004; 24: 5850-5862. (Pubitemid 38787970)
71. Sims AE, Spiteri E, Sims RJ, 3rd, et al., FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 2007; 14: 564-567. (Pubitemid 46871814)
72. Smogorzewska A, Matsuoka S, Vinciguerra P, et al., Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007; 129: 289-301. (Pubitemid 46584733)
73. Dorsman JC, Levitus M, Rockx D, et al., Identification of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol 2007; 29: 211-218. (Pubitemid 46855710)
74. Alpi AF, Patel KJ,. Monoubiquitylation in the Fanconi anemia DNA damage response pathway. DNA Repair (Amst) 2009; 8: 430-435.
75. Meetei AR, de Winter JP, Medhurst AL, et al., A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003; 35: 165-170. (Pubitemid 37187635)
76. Meetei AR, Sechi S, Wallisch M, et al., A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Mol Cell Biol 2003; 23: 3417-3426. (Pubitemid 36539175)
77. Ling C, Ishiai M, Ali AM, et al., FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J 2007; 26: 2104-2114. (Pubitemid 46625801)
78. Mosedale G, Niedzwiedz W, Alpi A, et al., The vertebrate Hef ortholog is a component of the Fanconi anemia tumor-suppressor pathway. Nat Struct Mol Biol 2005; 12: 763-771. (Pubitemid 43086250)
79. Gurtan AM, Stuckert P, D'Andrea AD,. The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem 2006; 281: 10896-10905. (Pubitemid 43855513)
80. Pace P, Johnson M, Tan WM, et al., FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J 2002; 21: 3414-3423. (Pubitemid 34760573)
81. Joo W, Xu G, Persky NS, et al., Structure of the FANCI-FANCD2 complex: insights into the Fanconi anemia DNA repair pathway. Science 2011; 333: 312-316.
82. Ishiai M, Kitao H, Smogorzewska A, et al., FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 2008; 15: 1138-1146.
83. Niedzwiedz W, Mosedale G, Johnson M, et al., The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. Mol Cell 2004; 15: 607-620. (Pubitemid 39141787)
84. Yamamoto K, Hirano S, Ishiai M, et al., Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. Mol Cell Biol 2005; 25: 34-43. (Pubitemid 40039797)
85. Rosado IV, Niedzwiedz W, Alpi AF, et al., The Walker B motif in avian FANCM is required to limit sister chromatid exchanges but is dispensable for DNA crosslink repair. Nucleic Acids Res 2009; 37: 4360-4370.
86. Bridge WL, Vandenberg CJ, Franklin RJ, et al., The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair. Nat Genet 2005; 37: 953-957. (Pubitemid 43086151)
87. Hirano S, Yamamoto K, Ishiai M, et al., Functional relationships of FANCC to homologous recombination, translesion synthesis, and BLM. EMBO J 2005; 24: 418-427. (Pubitemid 40216145)
88. Wilson JB, Yamamoto K, Marriott AS, et al., FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 2008; 27: 3641-3652. (Pubitemid 351912967)
89. Simpson LJ, Sale JE,. Rev1 is essential for DNA damage tolerance and non-templated immunoglobulin gene mutation in a vertebrate cell line. EMBO J 2003; 22: 1654-1664. (Pubitemid 36417413)
90. Arakawa H, Moldovan GL, Saribasak H, et al., A role for PCNA ubiquitination in immunoglobulin hypermutation. PLoS Biol 2006; 4: e366.
91. Nelson JR, Lawrence CW, Hinkle DC,. Deoxycytidyl transferase activity of yeast REV1 protein. Nature 1996; 382: 729-731. (Pubitemid 26282181)
92. Ross AL, Simpson LJ, Sale JE,. Vertebrate DNA damage tolerance requires the C-terminus but not BRCT or transferase domains of REV1. Nucleic Acids Res 2005; 33: 1280-1289. (Pubitemid 41439921)
93. Akkari YM, Bateman RL, Reifsteck CA, et al., The 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase. Mol Genet Metab 2001; 74: 403-412. (Pubitemid 34084649)
94. De Silva IU, McHugh PJ, Clingen PH, et al., Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000; 20: 7980-7990.
95. Raschle M, Knipscheer P, Enoiu M, et al., Mechanism of replication-coupled DNA interstrand crosslink repair. Cell 2008; 134: 969-980.
96. Knipscheer P, Raschle M, Smogorzewska A, et al., The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science 2009; 326: 1698-1701.
97. Long DT, Raschle M, Joukov V, et al., Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science 2011; 333: 84-87.
98. Ben-Yehoyada M, Wang LC, Kozekov ID, et al., Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell 2009; 35: 704-715.
99. Kratz K, Schopf B, Kaden S, et al., Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 2010; 142: 77-88.
100. Liu T, Ghosal G, Yuan J, et al., FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science 2010; 329: 693-696.
101. MacKay C, Declais AC, Lundin C, et al., Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010; 142: 65-76.
102. Smogorzewska A, Desetty R, Saito TT, et al., A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 2010; 39: 36-47.
103. Yoshikiyo K, Kratz K, Hirota K, et al., KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents. Proc Natl Acad Sci USA 2010; 107: 21553-21557.
104. Nomura Y, Adachi N, Koyama H,. Human Mus81 and FANCB independently contribute to repair of DNA damage during replication. Genes Cells 2007; 12: 1111-1122. (Pubitemid 47500525)
105. Hanada K, Budzowska M, Modesti M, et al., The structure-specific endonuclease Mus81-Eme1 promotes conversion of interstrand DNA crosslinks into double-strands breaks. EMBO J 2006; 25: 4921-4932. (Pubitemid 44607036)
106. Dendouga N, Gao H, Moechars D, et al., Disruption of murine Mus81 increases genomic instability and DNA damage sensitivity but does not promote tumorigenesis. Mol Cell Biol 2005; 25: 7569-7579. (Pubitemid 41170119)
107. McPherson JP, Lemmers B, Chahwan R, et al., Involvement of mammalian Mus81 in genome integrity and tumor suppression. Science 2004; 304: 1822-1826. (Pubitemid 38787902)
108. Sijbers AM, de Laat WL, Ariza RR, et al., Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996; 86: 811-822. (Pubitemid 26303449)
109. Niedernhofer LJ, Essers J, Weeda G, et al., The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells. EMBO J 2001; 20: 6540-6549. (Pubitemid 33078726)
110. Al-Minawi AZ, Saleh-Gohari N, Helleday T,. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res 2008; 36: 1-9.
111. Tomkinson AE, Bardwell AJ, Bardwell L, et al., Yeast DNA repair and recombination proteins Rad1 and Rad10 constitute a single-stranded-DNA endonuclease. Nature 1993; 362: 860-862. (Pubitemid 23132166)
112. Bardwell AJ, Bardwell L, Tomkinson AE, et al., Specific cleavage of model recombination and repair intermediates by the yeast Rad1-Rad10 DNA endonuclease. Science 1994; 265: 2082-2085. (Pubitemid 24325688)
113. McWhir J, Selfridge J, Harrison DJ, et al., Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nat Genet 1993; 5: 217-224. (Pubitemid 23330382)
114. Tian M, Shinkura R, Shinkura N, et al., Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol 2004; 24: 1200-1205. (Pubitemid 38112182)
115. Niedernhofer LJ, Garinis GA, Raams A, et al., A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 2006; 444: 1038-1043. (Pubitemid 46018517)
116. Bhagwat N, Olsen AL, Wang AT, et al., XPF-ERCC1 participates in the Fanconi anemia pathway of cross-link repair. Mol Cell Biol 2009; 29: 6427-6437.
117. -/- mice. EMBO J 2005; 24: 861-871. (Pubitemid 40396114)
118. Hsia KT, Millar MR, King S, et al., DNA repair gene Ercc1 is essential for normal spermatogenesis and oogenesis and for functional integrity of germ cell DNA in the mouse. Development 2003; 130: 369-378. (Pubitemid 36181491)
119. Ciccia A, McDonald N, West SC,. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem 2008; 77: 259-287.
120. de Laat WL, Appeldoorn E, Jaspers NG, et al., DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem 1998; 273: 7835-7842. (Pubitemid 28168827)
121. Fisher LA, Bessho M, Bessho T,. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro. J Biol Chem 2008; 283: 1275-1281.
122. Fekairi S, Scaglione S, Chahwan C, et al., Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell 2009; 138: 78-89.
123. Svendsen JM, Smogorzewska A, Sowa ME, et al., Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell 2009; 138: 63-77.
124. Munoz IM, Hain K, Declais AC, et al., Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol Cell 2009; 35: 116-127.
125. Andersen SL, Bergstralh DT, Kohl KP, et al., Drosophila MUS312 and the vertebrate ortholog BTBD12 interact with DNA structure-specific endonucleases in DNA repair and recombination. Mol Cell 2009; 35: 128-135.
126. Mullen JR, Kaliraman V, Ibrahim SS, et al., Requirement for three novel protein complexes in the absence of the Sgs1 DNA helicase in Saccharomyces cerevisiae. Genetics 2001; 157: 103-118.
127. + ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol 2007; 71: 416-425. (Pubitemid 46147908)
128. Yamamoto KN, Kobayashi S, Tsuda M, et al., Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci USA 2011; 108: 6492-6496.
129. Flott S, Rouse J,. Slx4 becomes phosphorylated after DNA damage in a Mec1/Tel1-dependent manner and is required for repair of DNA alkylation damage. Biochem J 2005; 391: 325-333. (Pubitemid 41532430)
130. Matsumura Y, Nishigori C, Yagi T, et al., Characterization of molecular defects in xeroderma pigmentosum group F in relation to its clinically mild symptoms. Hum Mol Genet 1998; 7: 969-974. (Pubitemid 28256589)
131. Volker M, Mone MJ, Karmakar P, et al., Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001; 8: 213-224. (Pubitemid 32772919)
132. Tsodikov OV, Ivanov D, Orelli B, et al., Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA. EMBO J 2007; 26: 4768-4776. (Pubitemid 350126799)
133. Orelli B, McClendon TB, Tsodikov OV, et al., The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways. J Biol Chem 2010; 285: 3705-3712.
134. Ridpath JR, Nakamura A, Tano K, et al., Cells deficient in the FANC/BRCA pathway are hypersensitive to plasma levels of formaldehyde. Cancer Res 2007; 67: 11117-11122. (Pubitemid 350248534)
135. Langevin F, Crossan GP, Rosado IV, et al., Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011; 475: 53-58.
136. Rosado IV, Langevin F, Crossan GP, et al., Essential requirement for formaldehyde catabolism in Fanconi anaemia DNA repair pathway deficient cells. Nat Struct Mol Biol 2011; (in press).
137. O'Brien PJ, Siraki AG, Shangari N,. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 2005; 35: 609-662. (Pubitemid 41693601)
138. Wang M, McIntee EJ, Cheng G, et al., Identification of DNA adducts of acetaldehyde. Chem Res Toxicol 2000; 13: 1149-1157.
139. Stein S, Lao Y, Yang IY, et al., Genotoxicity of acetaldehyde- and crotonaldehyde-induced 1,N2-propanodeoxyguanosine DNA adducts in human cells. Mutat Res 2006; 608: 1-7. (Pubitemid 44280042)
140. Garcia CC, Angeli JP, Freitas FP, et al., [13C2]-acetaldehyde promotes unequivocal formation of 1,N2-propano-2′-deoxyguanosine in human cells. J Am Chem Soc 2011; 133: 9140-9143.
141. Cheng G, Shi Y, Sturla SJ, et al., Reactions of formaldehyde plus acetaldehyde with deoxyguanosine and DNA: formation of cyclic deoxyguanosine adducts and formaldehyde cross-links. Chem Res Toxicol 2003; 16: 145-152. (Pubitemid 36245864)
142. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, et al., Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 1996; 14: 320-323.
143. Meetei AR, Levitus M, Xue Y, et al., X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 2004; 36: 1219-1224.
144. Strathdee CA, Gavish H, Shannon WR, et al., Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 1992; 356: 763-767.
145. Howlett NG, Taniguchi T, Olson S, et al., Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-609. (Pubitemid 34815345)
146. Yang H, Jeffrey PD, Miller J, et al., BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002; 297: 1837-1848. (Pubitemid 35024337)
147. Pace P, Mosedale G, Hodskinson MR, et al., Ku70 corrupts DNA repair in the absence of the Fanconi anemia pathway. Science 2010; 329: 219-223.
148. de Winter JP, Rooimans MA, van Der Weel L, et al., The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 2000; 24: 15-16. (Pubitemid 30041412)
149. Garcia-Higuera I, Kuang Y, Naf D, et al., Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex. Mol Cell Biol 1999; 19: 4866-4873. (Pubitemid 29289525)
150. Xia B, Dorsman JC, Ameziane N, et al., Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007; 39: 159-161. (Pubitemid 46184344)
151. Xia B, Sheng Q, Nakanishi K, et al., Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 2006; 22: 719-729.